2. Signaling Pathways
  3. Immunology/Inflammation
  4. Galectin

Galectin

Galectin

Related Products

PDF 0.13 MB

Galectins comprise a family of soluble β-galactoside binding proteins, which regulate key biological processes including cell growth, differentiation, apoptosis, and immune responses.

Sixteen galectin genes have been identified in animal kingdoms, 12 of which are expressed in humans. Galectins are usually classified into three groups based on their structure: (i) prototypical galectins (galectin-1 (Gal1), Gal2, Gal5, Gal7, Gal10, Gal11, Gal 13, Gal14, and Gal15), characterized by a single CRD, which can act as monomers or form homodimers; (ii) the chimeric galectin Gal3 (the only member of this class), with a single CRD and a large amino-terminal domain that facilitates the formation of oligomers; (iii) the tandem repeat galectins, with two CRDs that are linked through a small peptide domain; this group includes Gal4, Gal6, Gal8, Gal9, and Gal12. Recently, Galectins have been implicated as major therapeutic determinants that confer sensitivity or resistance to a wide range of anticancer modalities including chemotherapy, radiotherapy, targeted therapies, antiangiogenic therapies, and immunotherapies.

Galectin Isoform Specific Products:

Galectin Isoform Comparison
Cat. No. Product Name Effect Purity Chemical Structure
  • HY-114409
    GB1107
    		Inhibitor 99.92%
    GB1107 is a potent, selective, orally active inhibitor of Galectin-3 (Gal-3) with a Kd of 37 nM for human Galectin-3. GB1107 reduces human and mouse lung adenocarcinoma growth and blocks metastasis in the syngeneic model.
    GB1107
  • HY-19756
    OTX008
    		Inhibitor 99.09%
    OTX008 is a selective inhibitor of galectin-1.
    OTX008
  • HY-19940
    Olitigaltin
    		Inhibitor 99.75%
    TD139 is a synthetic galectin-3 inhibitor. TD139 has high affinity for galectin-3 with a Kd of 68 nM, a Kd of 0.22 μM for galectin-1, and a Kd of 38 μM for galectin-7.
    Olitigaltin
  • HY-130208
    Thiodigalactoside
    		Inhibitor 99.97%
    Thiodigalactoside (TDG) is an orally active and potent galectin (GAL) inhibitor with Kd values of 24 μM, 49 μM for GAL1 and GAL3, respectively. Thiodigalactoside, a non-metabolizable disaccharide, has anti-inflammatory and anti-cancer activity. Thiodigalactoside dramatically reduces body weight gain in diet-induced obese rats.
    Thiodigalactoside
  • HY-147041
    Selvigaltin
    		Inhibitor 98.87%
    Selvigaltin (GB1211) is an orally active galectin-3 small molecule inhibitor with an IC50 value of 12 nM in rabbits, showing anti-tumor activity. Selvigaltin decreases galectin-3 levels in the liver and reduces biomarkers of liver function (AST, ALT, bilirubin), inflammation (cells foci) and fibrosis (PSR, SHG), as well as decreasing the mRNA and protein expression of several key inflammation and fibrosis biomarkers (IL6, TGFβ3, SNAI2, collagen). Selvigaltin restores T-cell activity and induces less tumors and metastasis.
    Selvigaltin
  • HY-128852
    N-Acetyl-D-galactosamine, 98%
    		Inhibitor ≥98.0%
    N-Acetyl-D-galactosamine (GalNAc) is a terminal essential amino sugar derived from galactose and forms the antigens of blood group A in humans. N-Acetyl-D-galactosamine (GalNAc) interact with Soya bean agglutinin (SBA), hence decreasing the effects of SBA on cellular membrane permeability and tight junction protein expression in piglets. N-Acetyl-D-galactosamine (GalNAc) inhibits the hemagglutinating activity by the lectin.
    N-Acetyl-D-galactosamine, 98%
  • HY-162561
    GB1908
    		Inhibitor
    GB1908 is a selective and orally active galectin-1 inhibitor with Ki values of 57 nM and 72 nM for human and mouse galectin-1, respectively. GB1908 displays >50-fold selectivity over galectin-3. GB1908 can be used for the study of lung cancer.
    GB1908
  • HY-163900
    Galectin-8N-IN-2
    		Inhibitor
    Galectin-8N-IN-2 (compound 2) is a potent and selective Galectin-8N inhibitor with a Ki value of 74 μM.
    Galectin-8N-IN-2
  • HY-114440
    Belapectin
    		Inhibitor 99.33%
    Belapectin (GR-MD-02) is a Galectin-3 (Gal-3) inhibitor. Belapectin drives tumor-induced immunosuppression by inducing T cell Apoptosis. Belapectin promotes tumor regression and improves survival of tumor-bearing mice through a CD8+ T cell-dependent mechanism. Belapectin binds to Gal-3 with affinity Ki of 2.8 μM.
    Belapectin
  • HY-W150340
    β-Lactose
    		Inhibitor ≥98.0%
    β-Lactose is a disaccharide commonly found in milk and dairy products. It consists of two monosaccharides, glucose and galactose, linked by β-glycosidic bonds. β-Lactose has various applications in the food industry, especially as a sweetener and bulking agent. Furthermore, it can be used as a substrate for enzymes involved in lactose metabolism and as a model compound for studying carbohydrate-protein interactions.
    β-Lactose
  • HY-150235
    Galectin-8N-IN-1
    		Inhibitor 98.09%
    Galectin-8N-IN-1 (compound 19a) is a potent and selective galectin-8N inhibitor with a Kd value of 1.8 μM. Galectin-8N-IN-1 is a galectin-8N ligand. Galectin-8N-IN-1 can be used in research of immune system.
    Galectin-8N-IN-1
  • HY-146808
    Galectin-3 antagonist 1
    		Antagonist 99.77%
    Galectin-3 antagonist 1 (compound 15) is a potent and selective Galectin-3 (Gal-3) antagonist with Kd value of 5.3 μM. Meanwhile, Galectin-3 antagonist 1 binds to various Galectin with Kd values of 250 μM (Gal-4N), 18 μM (Gal-4C), 450 μM (Gal-8C), respectively.
    Galectin-3 antagonist 1
  • HY-P1592
    G3-C12
    		99.44%
    G3-C12 is a galectin-3 binding peptide, with Kd of 88 nM, and shows anticancer activity.
    G3-C12
  • HY-P1592A
    G3-C12 TFA
    		99.44%
    G3-C12 (TFA) is a galectin-3 binding peptide, with Kd of 88 nM, and shows anticancer activity.
    G3-C12 TFA
  • HY-155191
    Galectin-3/galectin-8-IN-1
    		Inhibitor
    Galectin-3/galectin-8-IN-1 (Compound 53) is a dual Galectin-3 and galectin-8 C-terminal domain inhibitor, with Kd values of 4.12 μM and 6.04 μM respectively. Galectin-3/galectin-8-IN-1 inhibits the MRC-5 lung fibroblast cells migration. Galectin-3/galectin-8-IN-1 can be used for research of cancer and tissue fibrosis.
    Galectin-3/galectin-8-IN-1
  • HY-157821
    Galectin-4-IN-3
    		Inhibitor
    Galectin-4-IN-3 (Compound 11) is a Galectin 4C inhibitor, with a Kd of 160 μM.
    Galectin-4-IN-3
  • HY-155192
    Galectin-3/galectin-8-IN-2
    		Inhibitor
    Galectin-3/galectin-8-IN-2 (Compound 57) is a dual Galectin-3 and galectin-8 C-terminal domain inhibitor, with Kd values of 12.8 μM and 2.06 μM respectively. Galectin-3/galectin-8-IN-2 inhibits the MRC-5 lung fibroblast cells migration. Galectin-3/galectin-8-IN-2 can be used for research of cancer and tissue fibrosis.
    Galectin-3/galectin-8-IN-2
  • HY-157822
    Galectin-8-IN-2
    		Inhibitor
    Galectin-8-IN-2 (Compound 10) is a galectin-8N inhibitor.
    Galectin-8-IN-2
  • HY-157824
    6Lac[6]Met
    		Inhibitor
    6Lac[6]Met is a galectin 4 inhibitor with an IC50 value 5 μM.
    6Lac[6]Met
  • HY-139831
    Galectin-8-IN-1
    Galectin-8-IN-1 is a selective ligand for the galectin-8 N-terminal domain (galectin-8N), with a Kd of 48 μM and 15-fold selectivity over galectin-3 and even better selectivity over the other mammalian galectins.
    Galectin-8-IN-1
Cat. No. Product Name / Synonyms Application Reactivity
Galectin Isoform Comparison

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.